Research
Hormonal
GLP-1 receptor agonists (e.g., tirzepatide, danuglipron) produce significant weight loss and glycemic improvement in type 2 diabetes and obesity, with weight loss and glycemic effects being partially independent mechanisms.
GLP-1 based medications like tirzepatide are highly effective for weight loss (15-21%) and blood sugar control. Be aware that gastrointestinal side effects are common and may lead some to stop treatment, but the dual benefit is significant. Discuss dosing strategies with your provider to manage side effects.
GoodSupportsHIGH confidence
An interesting post hoc study of 5378 participants with type 2 diabetes in phase 3 trials of tirzepatide analyzed the relationship found 'modest (correlation coefficients 0.1438-0.3130) association between HbA1c reduction and the effect on body weight,' suggesting that the two effects are at least partially independent.
Why this rating
Based on phase 3 trials and post-hoc analyses of large cohorts (n=5378 and n=411).
Source
A diabetes update
Zachary T. Bloomgarden · Journal of Diabetes · 2023
DOI 10.1111/1753-0407.13434
narrative_reviewCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Intensive blood pressure control (target <130/80 mmHg) reduces stroke and macroalbuminuria progression in type 2 diabetes compared to conventional control, without significantly affecting all-cause mortality.Strong
- Once-weekly insulin icodec provides glycemic control similar to once-daily insulin glargine with comparable hypoglycemia rates, potentially improving patient acceptability through reduced injection frequency.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →